Ashktorab Hassan, Smoot Duane T, Farzanmehr Haleh, Fidelia-Lambert Marie, Momen Bahram, Hylind Linda, Iacosozio-Dononue Christine, Carethers John M, Goel Ajay, Boland C Richard, Giardiello Francis M
Department of Medicine and Cancer Center, Howard University, Washington, DC 20060, USA.
Int J Cancer. 2005 Oct 10;116(6):914-9. doi: 10.1002/ijc.21062.
African Americans (AAs) have a 1.5 times higher risk of colorectal carcinoma (CRC) than Caucasians. Gene silencing through CpG island hypermethylation has been associated with the genesis or progression of microsatellite instability (MSI) largely due to 1 target for hypermethylation being the DNA mismatch repair gene hMLH1; there is anecdotal evidence of an increased incidence of MSI among AAs. P16 and hMLH1 can be inactivated by hypermethylation of their respective promoter regions, abrogating the ability to regulate cell proliferation and repair processes. We studied such methylation, as well as hMHS2 expression in colorectal cancers from AA patients to determine if MSI is associated with epigenetic silencing. Experiments were conducted on matched normal and colon cancer tissues from AA patients (n = 51). A total of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25 and BAT26) were used to evaluate MSI status. P16 and hMLH1 promoter methylation status was determined following bisulfite modification of DNA and using methylation specific PCR, while immunohistochemistry (IHC) was used to examine expression of hMLH1 and hMSH2. A total of 22 (43%) cancers demonstrated microsatellite instability-high (MSI-H), while 27 were microsatellite stable (MSS) and 2 were microsatellite instability-low (MSH-L). Most of the MSI-H tumors were proximal, well differentiated and highly mucinous. Most patients in the MSI-H group were females (68%). The p16 promoter was methylated in 19 of 47 (40%) tumors. A total of 7 of these CRCs demonstrated MSI-H (33%). The hMLH1 promoter was methylated in 29 of 34 (85%) tumors, of which 13 CRCs demonstrated MSI-H (87%). hMLH1 and hMSH2 staining was observed in 66% and 38% of MSI-H tumors, respectively. Overall, the prevalence of MSI-H colorectal tumor was 2-3-fold higher, while the defect in the percentage expression of mismatch repair (MMR) genes (hMLH1 and hMSH2) was similar in AA patients compared to the U.S. Caucasian population. Similar numbers of AA MSS tumors with p16 and hMLH1 methylation likely indicate hemimethylation of genes that might reflect environmental or genetic influences that might be more common in the AA population.
非裔美国人(AAs)患结直肠癌(CRC)的风险比白种人高1.5倍。通过CpG岛高甲基化导致的基因沉默与微卫星不稳定性(MSI)的发生或进展有关,这主要是因为高甲基化的一个靶点是DNA错配修复基因hMLH1;有轶事证据表明非裔美国人中MSI的发病率有所增加。P16和hMLH1可因其各自启动子区域的高甲基化而失活,从而丧失调节细胞增殖和修复过程的能力。我们研究了非裔美国患者结直肠癌中的这种甲基化以及hMHS2表达,以确定MSI是否与表观遗传沉默有关。对非裔美国患者(n = 51)匹配的正常组织和癌组织进行了实验。总共使用5个微卫星标记(D2S123、D5S346、D17S250、BAT25和BAT26)来评估MSI状态。在对DNA进行亚硫酸氢盐修饰后,使用甲基化特异性PCR确定P16和hMLH1启动子甲基化状态,同时使用免疫组织化学(IHC)检测hMLH1和hMSH2的表达。总共22例(43%)癌症表现为微卫星高度不稳定(MSI-H),27例为微卫星稳定(MSS),2例为微卫星低度不稳定(MSI-L)。大多数MSI-H肿瘤位于近端,分化良好且黏液丰富。MSI-H组中的大多数患者为女性(68%)。47例肿瘤中有19例(40%)p16启动子发生甲基化。这些结直肠癌中有7例表现为MSI-H(33%)。34例肿瘤中有29例(85%)hMLH1启动子发生甲基化,其中13例结直肠癌表现为MSI-H(87%)。分别在66%和38%的MSI-H肿瘤中观察到hMLH1和hMSH2染色。总体而言,MSI-H结直肠肿瘤的患病率高2至3倍,而非裔美国患者错配修复(MMR)基因(hMLH1和hMSH2)表达百分比的缺陷与美国白种人群相似。非裔美国MSS肿瘤中p16和hMLH1甲基化数量相似,这可能表明基因的半甲基化,这可能反映了在非裔美国人群中可能更常见的环境或遗传影响。